Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Narrative review: the promotion of gabapentin: an analysis of internal industry documents.

Steinman MA, Bero LA, Chren MM, Landefeld CS.

Ann Intern Med. 2006 Aug 15;145(4):284-93. Review.

PMID:
16908919
2.

Implementation of a publication strategy in the context of reporting biases. A case study based on new documents from Neurontin litigation.

Vedula SS, Goldman PS, Rona IJ, Greene TM, Dickersin K.

Trials. 2012 Aug 13;13:136. doi: 10.1186/1745-6215-13-136.

4.

Guidelines, editors, pharma and the biological paradigm shift.

Singh AR, Singh SA.

Mens Sana Monogr. 2007 Jan;5(1):27-30. doi: 10.4103/0973-1229.32176.

5.

Study of neurontin: titrate to effect, profile of safety (STEPS) trial: a narrative account of a gabapentin seeding trial.

Krumholz SD, Egilman DS, Ross JS.

Arch Intern Med. 2011 Jun 27;171(12):1100-7. doi: 10.1001/archinternmed.2011.241.

6.

Drug maker to pay $430 million in fines, civil damages.

[No authors listed]

FDA Consum. 2004 Jul-Aug;38(4):36-7.

7.

The ADVANTAGE seeding trial: a review of internal documents.

Hill KP, Ross JS, Egilman DS, Krumholz HM.

Ann Intern Med. 2008 Aug 19;149(4):251-8. Review.

PMID:
18711155
8.

Intended and unintended consequences of the gabapentin off-label marketing lawsuit among patients with bipolar disorder.

Chace MJ, Zhang F, Fullerton CA, Huskamp HA, Gilden D, Soumerai SB.

J Clin Psychiatry. 2012 Nov;73(11):1388-94. doi: 10.4088/JCP.12m07794.

PMID:
23146199
9.

The promotion of gabapentin.

Sapers BL.

Ann Intern Med. 2007 Feb 20;146(4):313; author reply 313-4. No abstract available.

PMID:
17310059
10.

The promotion of gabapentin.

Finucane TE.

Ann Intern Med. 2007 Feb 20;146(4):312-3; author reply 313-4. No abstract available.

PMID:
17310057
11.

Outcome reporting in industry-sponsored trials of gabapentin for off-label use.

Vedula SS, Bero L, Scherer RW, Dickersin K.

N Engl J Med. 2009 Nov 12;361(20):1963-71. doi: 10.1056/NEJMsa0906126.

12.

The promotion of gabapentin.

Peterson ED, Boyce K, Overstreet K.

Ann Intern Med. 2007 Feb 20;146(4):313; author reply 313-4. No abstract available.

PMID:
17310060
13.

False Claims Act prosecution did not deter off-label drug use in the case of neurontin.

Kesselheim AS, Darby D, Studdert DM, Glynn R, Levin R, Avorn J.

Health Aff (Millwood). 2011 Dec;30(12):2318-27. doi: 10.1377/hlthaff.2011.0370.

14.
15.

Disseminating findings from a drug class review: using best practices to inform prescription of antiepileptic drugs for bipolar disorder.

Melvin CL, Ranney LM, Carey TS, Evans WD, AED Dissemination Panel, Kreps G, Linden T, Oldham J.

J Psychiatr Pract. 2008 Mar;14 Suppl 1:44-56. doi: 10.1097/01.pra.0000333587.68118.9e. Erratum in: J Psychiatr Pract. 2008 May;14(3):193.

PMID:
19034209
16.

Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation.

Ross JS, Hill KP, Egilman DS, Krumholz HM.

JAMA. 2008 Apr 16;299(15):1800-12. doi: 10.1001/jama.299.15.1800.

PMID:
18413874
17.

Media coverage of off-label promotion: a content analysis of US newspapers.

Joshi AD, Patel DA, Holdford DA.

Res Social Adm Pharm. 2011 Sep;7(3):257-71. doi: 10.1016/j.sapharm.2010.06.003.

PMID:
21272550
18.

Characteristics and impact of drug detailing for gabapentin.

Steinman MA, Harper GM, Chren MM, Landefeld CS, Bero LA.

PLoS Med. 2007 Apr;4(4):e134.

19.

Publication planning: an effective corporate strategy to influence health professionals.

[No authors listed]

Prescrire Int. 2013 Dec;22(144):304, 306-7.

PMID:
24600737
20.

Patterns of prescribing antiepileptic drugs for bipolar disorder.

Kish-Doto J, Evans WD, Squire C, Williams P, Ranney LM, Melvin CL.

J Psychiatr Pract. 2008 Mar;14 Suppl 1:35-43. doi: 10.1097/01.pra.0000333586.60494.9a. Erratum in: J Psychiatr Pract. 2008 May;14(3):193.

PMID:
19034208
Items per page

Supplemental Content

Support Center